| Symbol | BTAX |
|---|---|
| Name | BIOSTAX CORP. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 32792 United States FL 2431 Aloma Ave. Suite 124 |
| Telephone | 888-391-9355 |
| Fax | — |
| — | |
| Website | http://www.immunetherapeutics.com |
| Incorporation | US |
| Incorporated On | 1993 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Turner, Stone & Company, L.L.P.; |
| Audit Status | UNAUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001559356 |
| Description | Immune Therapeutics, Inc. is a biotechnology company developing and seeking to commercialize patented therapies in emerging nations that combat chronic, life-threatening diseases by stimulating or rebalancing the immune system. Our technology platform is based on two interrelated cytokine drug therapies-Low-Dose Naltrexone (LDN) and Methionine Enkephalin (MENK)-which work by triggering opioid receptors on immune cells to activate various cells of the immune system. Additional info from OTC: Our technology platform is based on two interrelated cytokine drug therapies-Low-Dose Naltrexone (LDN) and Methionine Enkephalin (MENK)-which work by triggering opioid receptors on immune cells to activate various cells of the immune system. |
No news found.